Loading stock data…
Amarin Corporation plc (AMRN)
$13.55-0.05 (-0.37%)
Market ClosedLast close Jul 24
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amarin Corporation plc in the Healthcare sector is trading at $13.55 with a market capitalization of $323M. Wall Street consensus targets $12.00 (1 analysts), implying a -11.4% move over the next 12 months. The stock is currently near its 52-week low of $12.96, remaining 11.5% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: RSI 14 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -11.4% downside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 14) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $45.13M↓ | $49.22M↓ | $49.67M↓ | $72.74M↑ | $42.02M |
| Gross Profit | $17.77M↓ | $23.17M↑ | $22.21M↓ | $50.36M↑ | $25.13M |
| Operating Income | -$8.01M↓ | -$2.26M↓ | -$1.70M↓ | $6.77M↑ | -$16.75M |
| Net Income | -$10.51M↓ | -$1.22M↑ | -$7.74M↑ | -$14.14M↑ | -$15.70M |
Peer Comparison
JNJUNHPFE
Fundamentals
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$322.51M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-7.48%
Volume
Today's trading volume
54,916
Recent News
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.
Here's Why You Should Add Savara Stock to Your Portfolio Now
SVRA advances Molbreevi with positive long-term phase III data, an FDA review on track and expanded patent protection supporting its commercial outlook.
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate
ACAD wins FDA's Fast Track status for remlifanserin in Alzheimer's disease psychosis as its phase II data readout approaches and phase III enrollment advances.
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?
Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program.